Report Highlights
The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021.
Report Includes
- An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
Report Scope
Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.
Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.
Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, Asia-Pacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.
The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.
Report Includes
- An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2012, 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
Related Reports
Metabolomics: Technologies and Global Markets
The global market for metabolomics technologies is expected to grow from $16.4 billion in 2024 and is projected to reach $30.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2024 to 2029.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biological therapeutic drugs is expected to increase from $452.9 billion in 2023 to $823.4 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period of 2023-2028.
Global Markets for Research Antibodies
The global market for research antibodies is estimated to increase from $3.7 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 9.2% from 2023 through 2028.
Global Markets for Orphan Drugs
The global market for orphan drugs is expected to increase from $233.9 billion in 2023 to $415.2 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.2% during the forecast period of 2023-2028.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More